CAS 301326-22-7|CH-223191
| Common Name | CH-223191 | ||
|---|---|---|---|
| CAS Number | 301326-22-7 | Molecular Weight | 333.387 |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 469.4±45.0 °C at 760 mmHg |
| Molecular Formula | C19H19N5O | Melting Point | / |
| MSDS | ChineseUSA | Flash Point | 237.7±28.7 °C |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | 2-methyl-N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]pyrazole-3-carboxamide |
|---|---|
| Synonym | More Synonyms |
CH-223191 BiologicalActivity
| Description | CH-223191 is a potent and specific antagonist of aryl hydrocarbon receptor (AhR). CH-223191 blocks the binding of TCDD to AhR with an IC50 of 0.03 µM. |
|---|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>Inflammation/Immunology |
| References | [1]. Zhao B, et al. CH223191 is a ligand-selective antagonist of the Ah (Dioxin) receptor. Toxicol Sci. 2010 Oct;117(2):393-403. [2]. Kim SH, et al. Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor. Mol Pharmacol. 2006 Jun;69(6):1871-8. |
Chemical & Physical Properties
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 469.4±45.0 °C at 760 mmHg |
| Molecular Formula | C19H19N5O |
| Molecular Weight | 333.387 |
| Flash Point | 237.7±28.7 °C |
| Exact Mass | 333.158966 |
| PSA | 75.13000 |
| LogP | 3.48 |
| Appearance of Characters | orange-brown |
| Vapour Pressure | 0.0±1.2 mmHg at 25°C |
| Index of Refraction | 1.633 |
| InChIKey | LKTNEXPODAWWFM-UHFFFAOYSA-N |
| SMILES | Cc1ccccc1N=Nc1ccc(NC(=O)c2ccnn2C)c(C)c1 |
| Storage condition | Store at +4°C |
| Water Solubility | DMSO: ≥20mg/mL |
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 |
| Hazard Codes | Xn |
| Risk Phrases | 22 |
| Safety Phrases | 22 |
| RIDADR | NONH for all modes of transport |
Articles6
More Articles| The aryl hydrocarbon receptor suppresses osteoblast proliferation and differentiation through the activation of the ERK signaling pathway. Toxicol. Appl. Pharmacol. 280(3) , 502-10, (2014) Ahr activation is known to be associated with synovitis and exacerbated rheumatoid arthritis (RA), but its contributions to bone loss have not been completely elucidated. Osteoblast proliferation and ... | |
| In-vitro evidence of enhanced breast cancer resistance protein-mediated intestinal urate secretion by uremic toxins in Caco-2 cells. J. Pharm. Pharmacol. 67(2) , 170-7, (2015) It has been reported that intestinal urate excretion is increased at chronic kidney disease (CKD) state. In this report, whether uremic toxins are involved in the upregulation of intestinal breast can... | |
| Analysis of Glycogen Synthase Kinase Inhibitors That Regulate Cytochrome P450 Expression in Primary Human Hepatocytes by Activation of β-Catenin, Aryl Hydrocarbon Receptor and Pregnane X Receptor Signaling. Toxicol. Sci. 148 , 261-75, (2015) Cytochrome P450 (CYP) expression and activity are not homogeneous in the liver lobules. Indeed, CYPs are mainly expressed and induced in centrilobular hepatocytes. The wingless-type MMTV integration s... |
Synonyms
| 2-Methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide |
| 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide |
| UNII-HYE7315Z4C |
| 1H-Pyrazole-5-carboxamide, 1-methyl-N-[2-methyl-4-[(E)-2-(2-methylphenyl)diazenyl]phenyl]- |
| 1-Methyl-N-{2-methyl-4-[(E)-(2-methylphenyl)diazenyl]phenyl}-1H-pyrazole-5-carboxamide |
| AhR Antagonist |
| CH-223191 |
